Gilead Sciences, Inc. showed a strengthening of its core business in the second quarter of 2023 as sales climbed higher even when factoring in the COVID-19 antiviral drug Veklury (remdesivir), which had carried Gilead’s sales during the pandemic and whose declines had in multiple quarters caused the company’s revenues to fall, remain flat or rise only slightly on a year-over-year basis.
Gilead Keeps Climbing Out Of Veklury’s Shadow As Core Business Growth Strengthens
Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.
More from Earnings
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.